Awakn Life Sciences Announces Closing of Private Placement

Awakn Life Sciences has announced that they have closed a non-brokered private placement through the issuance of 2,031,250 units at a price of $1.60 per Unit for gross proceeds of $3,250,000.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

πŸ“° Weekly newsletter about the psychedelic research

βœ”οΈ Unlimited access to our database and original articles

πŸ–ŠοΈ Add (private) notes and comments to each page

Make an account
Category Press Release
Published in Bloomberg

Companies Featured

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.

Inline Feedbacks
View all comments